PD-L1阳性-话题@MedSci

#PD-L1阳性#

18篇内容 | 922人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1400856, encodeId=e7471400856ce, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性, objectType=article, longId=728373, objectId=4ee9e283734e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee9e283734e, replyNumber=0, likeNumber=59, createdTime=2022-06-02, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee9e283734e, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ee9e283734e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400855, encodeId=3b4b1400855b7, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, objectType=article, longId=727300, objectId=7f29e2730032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f29e2730032, replyNumber=0, likeNumber=33, createdTime=2022-05-20, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f29e2730032, moduleTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f29e2730032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400854, encodeId=8c86140085498, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=52, createdTime=2022-04-12, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400853, encodeId=787614008533b, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, objectType=article, longId=723564, objectId=5743e2356484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5743e2356484, replyNumber=0, likeNumber=46, createdTime=2022-04-07, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5743e2356484, moduleTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5743e2356484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400852, encodeId=602e1400852f5, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=36, createdTime=2022-02-25, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400851, encodeId=bf3c140085110, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=36, createdTime=2021-09-13, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400850, encodeId=09ef14008500b, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, objectType=article, longId=204210, objectId=9f312042101b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f312042101b, replyNumber=0, likeNumber=35, createdTime=2020-12-08, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f312042101b, moduleTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f312042101b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400849, encodeId=af7b1400849a8, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=T药+白蛋白紫杉醇一线治疗三阴乳腺癌：PD-L1阳性人群OS获益显著，亚洲人群不佳, objectType=article, longId=201088, objectId=5c682010884c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c682010884c, replyNumber=0, likeNumber=33, createdTime=2020-09-24, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c682010884c, moduleTitle=T药+白蛋白紫杉醇一线治疗三阴乳腺癌：PD-L1阳性人群OS获益显著，亚洲人群不佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c682010884c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400848, encodeId=5aa314008483b, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=Cancer Cell亮点 | 洪明奇团队开发新方法提高PD-L1阳性检出率, objectType=article, longId=176346, objectId=05651e634668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05651e634668, replyNumber=0, likeNumber=39, createdTime=2019-07-30, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05651e634668, moduleTitle=Cancer Cell亮点 | 洪明奇团队开发新方法提高PD-L1阳性检出率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05651e634668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400847, encodeId=9b43140084ed4, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳, objectType=article, longId=122519, objectId=7e5f122519c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e5f122519c5, replyNumber=0, likeNumber=39, createdTime=2017-12-08, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e5f122519c5, moduleTitle=JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e5f122519c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400846, encodeId=d1d7140084689, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性, objectType=article, longId=118912, objectId=d9371189127f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9371189127f, replyNumber=0, likeNumber=38, createdTime=2017-11-07, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9371189127f, moduleTitle=JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9371189127f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400845, encodeId=03bf1400845b6, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=JCO：派姆单抗治疗PD-L1阳性鼻咽癌患者的安全性及抗肿瘤活性研究, objectType=article, longId=111067, objectId=776311106e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776311106e61, replyNumber=0, likeNumber=37, createdTime=2017-08-29, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776311106e61, moduleTitle=JCO：派姆单抗治疗PD-L1阳性鼻咽癌患者的安全性及抗肿瘤活性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=776311106e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400844, encodeId=93f814008444d, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=J Clin Oncol：Atezolizumab一线治疗PD-L1阳性晚期NSCLC有效，OS接近2年, objectType=article, longId=102582, objectId=702f102582ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=702f102582ee, replyNumber=0, likeNumber=48, createdTime=2017-06-21, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=702f102582ee, moduleTitle=J Clin Oncol：Atezolizumab一线治疗PD-L1阳性晚期NSCLC有效，OS接近2年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=702f102582ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400843, encodeId=7ce21400843a7, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=88246, objectId=abae8824611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abae8824611, replyNumber=0, likeNumber=29, createdTime=2017-02-05, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abae8824611, moduleTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abae8824611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400842, encodeId=44791400842ad, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=85252, objectId=aeb08525282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb08525282, replyNumber=0, likeNumber=48, createdTime=2016-12-25, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb08525282, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb08525282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400841, encodeId=96a4140084109, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, objectType=article, longId=79695, objectId=2555e969519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2555e969519, replyNumber=0, likeNumber=45, createdTime=2016-10-11, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2555e969519, moduleTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2555e969519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400840, encodeId=69611400840bb, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, objectType=article, longId=77041, objectId=3754e70412b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3754e70412b, replyNumber=0, likeNumber=30, createdTime=2016-09-10, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3754e70412b, moduleTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3754e70412b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400839, encodeId=0a97140083930, content=<a href='/topic/show?id=4ce31393169' target=_blank style='color:#2F92EE;'>#PD-L1阳性#</a>, objectTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, objectType=article, longId=60882, objectId=3e5560882c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5560882c0, replyNumber=0, likeNumber=30, createdTime=2015-12-22, rootId=0, userName=klivis, userId=55c12269876, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5560882c0, moduleTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5560882c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1阳性

2020-05-29

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性

2022-06-02

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC

2022-05-20

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）

2022-04-07

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-02-25

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-09-13

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌

2020-12-08

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

T药+白蛋白紫杉醇一线治疗三阴乳腺癌：PD-L1阳性人群OS获益显著，亚洲人群不佳

2020-09-24

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

Cancer Cell亮点 | 洪明奇团队开发新方法提高PD-L1阳性检出率

2019-07-30

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳

2017-12-08

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性

2017-11-07

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

JCO：派姆单抗治疗PD-L1阳性鼻咽癌患者的安全性及抗肿瘤活性研究

2017-08-29

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

J Clin Oncol：Atezolizumab一线治疗PD-L1阳性晚期NSCLC有效，OS接近2年

2017-06-21

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2017-02-05

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2016-12-25

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著

2016-10-11

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格

2016-09-10

klivis (审核中...)

前往app查看评论内容

#PD-L1阳性#

Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期

2015-12-22

科室
- - 订阅+
  - 更多科室
工具
服务